ÈËÆÞÖгöÊÓƵ

Journal Article

1. Amann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. J Behav Med, 47(3), 405-421. ()
2. Semaan A, Bernard V, Wong JW, Makino Y, Swartzlander DB, Rajapakshe KI, Lee JJ, Officer A, Schmidt CM, Wu HH, Scaife CL, Affolter K, Nachmanson D, Firpo MA, Yip-Schneider M, Lowy AM, Harismendy O, Sen S, Maitra A, Jakubek YA, Guerrero PA (2023). Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. Cancer Res Commun, 3(10), 2062-2073. ()
3. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
4. Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD (2023). Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(7), 753-782. ()
5. DAngelica MI, Ellis RJ, Liu JB, Brajcich BC, Gnen M, Thompson VM, Cohen ME, Seo SK, Zabor EC, Babicky ML, Bentrem DJ, Behrman SW, Bertens KA, Celinski SA, Chan CHF, Dillhoff M, Dixon MEB, Fernandez-Del Castillo C, Gholami S, House MG, Karanicolas PJ, Lavu H, Maithel SK, McAuliffe JC, Ott MJ, Reames BN, Sanford DE, Sarpel U, Scaife CL, Serrano PE, Smith T, Snyder RA, Talamonti MS, Weber SM, Yopp AC, Pitt HA, Ko CY (2023). Piperacillin-Tazobactam Compared with Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA, 329(18), 1579-1588. ()
6. Himbert C, Ose J, Gigic B, Viskochil R, Santuci K, Lin T, Ashworth A, Cohan JN, Scaife CL, Jedrzkiewicz J, Damerell V, Atkins KM, Gong J, Mutch MG, Bernadt C, Felder S, Sanchez J, Cohen SA, Krane MK, Hinkle N, Wood E, Peoples AR, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Shibata D, Boucher K, Round JL, Ulrich AB, Schneider M, Huang LC, Hardikar S, Ulrich CM (2023). Associations of combined physical activity and body mass index groups with colorectal cancer survival outcomes. BMC Cancer, 23(1), 300. ()
7. Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill SJ (2023). Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO Clin Cancer Inform, 7, e2200160. ()
8. Hoskins EL, Samorodnitsky E, Wing MR, Reeser JW, Hopkins JF, Murugesan K, Kuang Z, Vella R, Stein L, Risch Z, Yu L, Adebola S, Paruchuri A, Carpten J, Chahoud J, Edge S, Kolesar J, McCarter M, Nepple KG, Reilley M, Scaife C, Tripathi A, Single N, Huang RSP, Albacker LA, Roychowdhury S (2024). Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations. JCO Precis Oncol, 7, e2200300. ()
9. Himbert C, Warby CA, Gigic B, Ose J, Lin T, Viskochil R, Peoples AR, Ashworth A, Schrotz-King P, Scaife CL, Cohan JN, Jedrzkiewicz J, Schirmacher P, Grady WM, Cohen SA, Krane M, Figueiredo JC, Toriola AT, Siegel EM, Shibata D, Round JL, Huang LC, Li CI, Schneider M, Ulrich A, Hardikar S, Ulrich CM (2022). Associations of Individual and Combined Physical Activity and Body Mass Index Groups with Proinflammatory Biomarkers among Colorectal Cancer Patients. Cancer Epidemiol Biomarkers Prev, 31(12), 2148-2156. ()
10. Bleicher J, Place A, Harris AHS, Scaife CL, Huang LC (2022). Patient Perceptions of Decision-making and Quality-of-life Following Surgical Resection of Pancreatic Adenocarcinoma: A Mixed-methods Study. Ann Surg Open, 3(4), e214. ()
11. Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL, Ulrich CM (2022). Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients. Am J Cancer Res, 12(10), 4789-4801. ()
12. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control, 33(7), 939-950. ()
13. Hernandez S, Parra ER, Uraoka N, Tang X, Shen Y, Qiao W, Jiang M, Zhang S, Mino B, Lu W, Pandurengan R, Haymaker C, Affolter K, Scaife CL, Yip-Schneider M, Schmidt CM, Firpo MA, Mulvihill SJ, Koay EJ, Wang H, Wistuba II, Maitra A, Solis LM, Sen S (2021). Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. Clin Cancer Res, 28(9), 1938-1947. ()
14. Gutnik L, Bleicher J, Davis A, McLeod MC, McCrum M, Scaife C (2022). American Indian/Alaska native access to colorectal cancer screening: Does gastroenterologist density matter? Am J Surg, 224, 965-970. ()
15. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer, 1-9. ()
16. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural ÈËÆÞÖгöÊÓƵ, 38(4), 886-899. ()
17. Bleicher J, Fender Z, Johnson JE, Cain BT, Phan K, Powers D, Wei G, Presson AP, Kwok A, Pickron TB, Scaife CL, Huang LC (2021). Use of post-discharge opioid consumption patterns as a tool for evaluating opioid prescribing guidelines. Am J Surg, 224(1 Pt A), 58-63. ()
18. Himbert C, Figueiredo JC, Shibata D, Ose J, Lin T, Huang LC, Peoples AR, Scaife CL, Pickron B, Lambert L, Cohan JN, Bronner M, Felder S, Sanchez J, Dessureault S, Coppola D, Hoffman DM, Nasseri YF, Decker RW, Zaghiyan K, Murrell ZA, Hendifar A, Gong J, Firoozmand E, Gangi A, Moore BA, Cologne KG, El-Masry MS, Hinkle N, Monroe J, Mutch M, Bernadt C, Chatterjee D, Sinanan M, Cohen SA, Wallin U, Grady WM, Lampe PD, Reddi D, Krane M, Fichera A, Moonka R, Herpel E, Schirmacher P, Kloor M, von Knebel-Doeberitz M, Nattenmueller J, Kauczor HU, Swanson E, Jedrzkiewicz J, Schmit SL, Gigic B, Ulrich AB, Toriola AT, Siegel EM, Li CI, Ulrich CM, Hardikar S (2021). Clinical characteristics and outcomes of colorectal cancer in the colocare study: Differences by age of onset. Cancers (Basel), 13(15). ()
19. Himbert C, Figueiredo JC, Shibata D, Ose J, Lin T, Huang LC, Peoples AR, Scaife CL, Pickron B, Lambert L, Cohan JN, Bronner M, Felder S, Sanchez J, Dessureault S, Coppola D, Hoffman DM, Nasseri YF, Decker RW, Zaghiyan K, Murrell ZA, Hendifar A, Gong J, Firoozmand E, Gangi A, Moore BA, Cologne KG, El-Masry MS, Hinkle N, Monroe J, Mutch M, Bernadt C, Chatterjee D, Sinanan M, Cohen SA, Wallin U, Grady WM, Lampe PD, Reddi D, Krane M, Fichera A, Moonka R, Herpel E, Schirmacher P, Kloor M, von Knebel-Doeberitz M, Nattenmueller J, Kauczor HU, Swanson E, Jedrzkiewicz J, Schmit SL, Gigic B, Ulrich AB, Toriola AT, Siegel EM, Li CI, Ulrich CM, Hardikar S (2021). Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset. Cancers (Basel), 13(15). ()
20. Affolter KE, Hellwig S, Nix DA, Bronner MP, Thomas A, Fuertes CL, Hamil CL, Garrido-Laguna I, Scaife CL, Mulvihill SJ, Underhill HR (2021). Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia, 23(9), 859-869. ()
21. Bleicher J, Lambert LA, Scaife CL, Colonna A (2021). Current management of malignant bowel obstructions: A survey of acute care surgeons and surgical oncologists. Trauma Surg Acute Care Open, 6(1). ()
22. Bleicher J, Lambert LA, Scaife CL, Colonna A (2021). Current management of malignant bowel obstructions: a survey of acute care surgeons and surgical oncologists. Trauma Surg Acute Care Open, 6(1), e000755. ()
23. Swords DS, Scaife CL (2020). Decompositions of the Contribution of Treatment Disparities to Survival Disparities in Stage I-II Pancreatic Adenocarcinoma. Ann Surg Oncol, 28(6), 3157-3168. ()
24. Swords DS, Scaife CL (2020). ASO Author Reflections: Using Causal Mediation Analysis to Understand the Proportion of Survival Disparities Mediated by Potentially Modifiable Treatment Factors. Ann Surg Oncol, 28(6), 3169-3170. ()
25. Eisele Y, Mallea PM, Gigic B, Stephens WZ, Warby CA, Buhrke K, Lin T, Boehm J, Schrotz-King P, Hardikar S, Huang LC, Pickron TB, Scaife CL, Viskochil R, Koelsch T, Peoples AR, Pletneva MA, Bronner M, Schneider M, Ulrich AB, Swanson EA, Toriola AT, Shibata D, Li CI, Siegel EM, Figueiredo J, Janssen KP, Hauner H, Round J, Ulrich CM, Holowatyj AN, Ose J (2021). Fusobacterium nucleatum and Clinicopathologic Features of Colorectal Cancer: Results From the ColoCare Study. Clin Colorectal Cancer, 20(3), e165-e172. ()
26. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2020). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675. ()
27. Bleicher J, Cohan JN, Huang LC, Peche W, Pickron TB, Scaife CL, Bowles TL, Hyngstrom JR, Asare EA (2020). Trends in the management of anorectal melanoma: A multi-institutional retrospective study and review of the world literature. World J Gastroenterol, 27(3), 267-280. ()
28. Swords DS, Mulvihill SJ, Brooke BS, Stoddard GJ, Firpo MA, Scaife CL (2019). County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. Ann Surg, 272(6), 1102-1109. ()
29. Stokes SM, Scaife CL, Brooke BS, Glasgow RE, Mulvihill SJ, Finlayson SRG, Varghese TK Jr (2020). Hospital Costs Following Surgical Complications: A Value-driven Outcomes Analysis of Cost Savings Due to Complication Prevention. Ann Surg, 275, e375-e381. ()
30. Geijsen AJMR, Ulvik A, Gigic B, Kok DE, van Duijnhoven FJB, Holowatyj AN, Brezina S, van Roekel EH, Baierl A, Bergmann MM, Bhm J, Bours MJL, Brenner H, Breukink SO, Bronner MP, Chang-Claude J, de Wilt JHW, Grady WM, Grnberger T, Gumpenberger T, Herpel E, Hoffmeister M, Huang LC, Jedrzkiewicz JD, Keulen ETP, Kiblawi R, Klsch T, Koole JL, Kosma K, Kouwenhoven EA, Kruyt FM, Kvalheim G, Li CI, Lin T, Ose J, Pickron TB, Scaife CL, Schirmacher P, Schneider MA, Schrotz-King P, Singer MC, Swanson ER, van Duijvendijk P, van Halteren HK, van Zutphen M, Vickers K, Vogelaar FJ, Wesselink E, Habermann N, Ulrich AB, Ueland PM, Weijenberg MP, Gsur A, Ulrich CM, Kampman E (2020). Circulating Folate and Folic Acid Concentrations: Associations With Colorectal Cancer Recurrence and Survival. JNCI Cancer Spectr, 4(5), pkaa051. ()
31. Bleicher J, Shepherd HM, Scaife CL (2020). Hemoglobin A1c as a marker to stratify diabetes risk following pancreaticoduodenectomy. Surg Open Sci, 2(3), 136-139. ()
32. Swords DS, Mulvihill SJ, Brooke BS, Firpo MA, Scaife CL (2019). Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. Ann Surg Oncol, 27(2), 333-341. ()
33. Swords DS, Scaife CL (2019). ASO Author Reflections: Socioeconomic Disparities in Use of Surgery for Gastrointestinal Cancers Are Large and Impactful in Poor-Prognosis Cancers. Ann Surg Oncol, 27(2), 342-343. ()
34. Bleicher J, Shepherd HM, Scaife CL (2020). Hemoglobin A1c as a marker to stratify diabetes risk following pancreaticoduodenectomy. Surg Open Sci, 2(3), 136-139. ()
35. Varedi D, Frigerio A, Scaife C, Hull C (2019). A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. Dermatol Online J, 25(3). ()
36. Acher AW, Bleicher J, Cannon A, Scaife C (2018). Advances in surgery for pancreatic cancer. J Gastrointest Oncol, 9(6), 1037-1043. ()
37. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5). ()
38. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 3(1). ()
39. Granger JH, Skuratovsky A, Porter MD, Scaife CL, Shea JE, Li Q, Wang S (2017). Coupling solid-phase microextractions and surface-enhanced Raman scattering: Towards a point-of-need tool for hepatic cancer screening. Anal Methods, 9(32), 4641-4646. ()
40. Shen Y, Zificsak CA, Shea JE, Lao X, Bollt O, Li X, Lisko JG, Theroff JP, Scaife CL, Ator MA, Ruggeri BA, Dorsey BD, Kuwada SK (2015). Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread. J Med Chem, 58(3), 1140-58. ()
41. Russell KW, Scaife CL, Weber DC, Windsor JS, Wheeler AR, Smith WR, Wedmore I, McIntosh SE, Lieberman JR (2014). Wilderness Medical Society practice guidelines for the treatment of acute pain in remote environments: 2014 update. Wilderness Environ Med, 25(4 Suppl), S96-104. ()
42. Bowen ME, Mone MC, Nelson EW, Scaife CL (2014). Image-guided placement of long-term central venous catheters reduces complications and cost. Am J Surg, 208(6), 937-41; discussion 941. ()
43. Chen Y, Youn P, Pysher TJ, Scaife CL, Furgeson DY (2014). Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates. Int J Hyperthermia, 30(8), 550-64. ()
44. Martin P, Noonan S, Mullen MP, Scaife C, Tosetto M, Nolan B, Wynne K, Hyland J, Sheahan K, Elia G, ODonoghue D, Fennelly D, OSullivan J (2014). Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer, 14, 887. ()
45. Benson AB 3rd, DAngelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H (2014). Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw, 12(8), 1152-82. ()
46. Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ (2014). Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (Oxford), 16(7), 670-6. ()
47. Jackson KL, Glasgow RE, Mone MC, Sheng X, Mulvihill SJ, Scaife CL (2014). Does travel distance influence length of stay in elective pancreatic surgery? HPB (Oxford), 16(6), 543-9. ()
48. Russell KW, Scaife CL, Weber DC, Windsor JS, Wheeler AR, Smith W, Wedmore I, McIntosh SE, Lieberman JR (2014). Wilderness Medical Society practice guidelines for the treatment of acute pain in remote environments. Wilderness Environ Med, 25(1), 41-9. ()
49. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ (2014). Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure. HPB (Oxford), 16(1), 62-9. ()
50. Nelson ET, Gross ME, Mone MC, Hansen HJ, Nelson EW, Scaife CL (2013). A survey of American College of Surgery fellows evaluating their use of antibiotic prophylaxis in the placement of subcutaneously implanted central venous access ports. Am J Surg, 206(6), 1034-9; discussion 1039-40. ()
51. Scaife CL, Hartz A, Pappas L, Pelletier P, He T, Glasgow RE, Mulvihill SJ (2013). Association between postoperative complications and clinical cancer outcomes. Ann Surg Oncol, 20(13), 4063-6. ()
52. Russell KW, Mone MC, Scaife CL (2013). Umbilical paracentesis for acute hernia reduction in cirrhotic patients. BMJ Case Rep. ()
53. Russell KW, Mone MC, Scaife CL (2013). Umbilical paracentesis for acute hernia reduction in cirrhotic patients.LID - 10.1136/bcr-2013-201304 [doi]LID - bcr2013201304 [pii]. BMJ Case Rep, 2013. ()
54. Witt BL, Kristen Hilden RN, Scaife C, Chadwick B, Layfield L, Cory Johnston W, Safaee M, Siddiqui A, Adler DG (2013). Identification of factors predictive of malignancy in patients with atypical biliary brushing results obtained via ERCP. Diagn Cytopathol, 41(8), 682-8. ()
55. Rapoport N, Payne A, Dillon C, Shea J, Scaife C, Gupta R (2013). Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model. J Ther Ultrasound, 1(1). ()
56. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ (2013). The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med, 13(3), 340-51. ()
57. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ (2013). Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas, 42(2), 193-7. ()
58. Jackson KL, Glasgow RE, Hill BR, Mone MC, Sklow B, Scaife CL, Sheng X, Peche WJ (2013). Does travel distance influence length of stay in elective colorectal surgery? Dis Colon Rectum, 56(3), 367-73. ()
59. Rapoport N, Payne A, Dillon C, Shea J, Scaife C, Gupta R (2013). Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model. J Ther Ultrasound, 1, 11. ()
60. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, Gouw L, Andtbacka RH, Chan BK, Rodesch CK, Jimenez A, Cano P, Jones KA, Oyedeji CO, Martins T, Hill HR, Schumacher J, Willmore C, Scaife CL, Ward JH, Morton K, Randall RL, Lazar AJ, Patel S, Trent JC, Frazier ML, Lin P, Jensen P, Benjamin RS (2012). Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother, 61(7), 1113-24. ()
61. Hazard L, Jones K, Shaban A, Anker C, Scaife C, Weis J, Mulvihill S (2012). Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. J Gastrointest Cancer, 43(2), 258-66. ()
62. Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE (2012). Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis. HPB (Oxford), 14(1), 26-31. ()
63. Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE (2012). Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis. HPB (Oxford), 14(1), 26-31. ()
64. Gross ME, Nelson ET, Mone MC, Hansen HJ, Sklow B, Glasgow RE, Scaife CL (2011). A comparison of postoperative outcomes utilizing a continuous preperitoneal infusion versus epidural for midline laparotomy. Am J Surg, 202(6), 765-9; discussion 770. ()
65. Rapoport N, Nam KH, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X, Kim T, Shea J, Scaife C, Parker DL, Jeong EK, Kennedy AM (2011). Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release, 153(1), 4-15. ()
66. Kennedy SA, Scaife C, Dunn MJ, Wood AE, Watson RW (2011). Benefits of heat treatment to the protease packed neutrophil for proteome analysis: halting protein degradation. Proteomics, 11(12), 2560-4. ()
67. Shea JE, Nam KH, Rapoport N, Scaife CL (2011). Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford), 13(3), 153-7. ()
68. Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL, Murtaugh LC (2011). Lineage tracing reveals the dynamic contribution of Hes1+ cells to the developing and adult pancreas. Development, 138(3), 431-41. ()
69. Shea J, Nam K, Rapoport N, Scaife C (2011). Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. HPB (Oxford), 13(3), 153-157. ()
70. Scaife CL, Gross ME, Mone MC, Hansen HJ, Litz CL, Nelson ET, Anderson CJ, Wagner G, Gawlick U, Nelson EW (2010). Antibiotic prophylaxis in the placement of totally implanted central venous access ports. Am J Surg, 200(6), 719-22; disussion 722-3. ()
71. Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ (2010). Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 19(10), 2605-10. ()
72. Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ (2010). Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. HPB (Oxford), 12(5), 352-8. ()
73. Deer EL, Gonzlez-Hernndez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010). Phenotype and genotype of pancreatic cancer cell lines. Pancreas, 39(4), 425-35. ()
74. Rapoport N, Kennedy AM, Shea JE, Scaife CL, Nam KH (2010). Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging. Mol Pharm, 7(1), 22-31. ()
75. Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PWT, Pollock RE, Feig BW (2003). Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg, 186(6), 665-669. ()

Review

1. Swords DS, Firpo MA, Scaife CL, Mulvihill SJ (2016). Biomarkers in pancreatic adenocarcinoma: Current perspectives. [Review]. Onco Targets Ther, 9, 7459-7467. ()
2. Deer EL, Gonzlez-Hernndez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010). Phenotype and genotype of pancreatic cancer cell lines. [Review]. Pancreas, 39(4), 425-435. ()
3. Scaife CL, Rodriguez-Bigas MA (2003). Lynch syndrome: Implications for the surgeon. [Review]. Clin Colorectal Cancer, 3(2), 92-98. ()

Book Chapter

1. Scaife C (2008). Liver. In Scaife C (Ed.), Surgery: Basic Science and Clinical Evidence: Second Edition (pp. 943-961). ()

Conference Proceedings

1. Rapoport N, Nam KH, Christensen DA, Kennedy AM, Parker DL, Payne AH, Todd N, Shea JE, Scaife CL (2011). Multimodal perfluorocarbon nanoemulsions for 19F MRI, ultrasonography, and catalysis of MRgFUS-mediated drug delivery. In Rapoport N|Nam KH|Christensen DA|Kennedy AM|Parker DL|Payne AH|Todd N|Shea JE|Scaife CL (Ed.), AIP Conf Proc, 1359, 451-456. ()
2. Rapoport N, Nam KH, Christensen DA, Kennedy AM, Shea JE, Scaife CL (2010). Ultrasound-enhanced nanotherapy of pancreatic cancer. In Rapoport N|Nam KH|Christensen DA|Kennedy AM|Shea JE|Scaife CL (Ed.), AIP Conf Proc, 1215, 123-126. ()

Editorial

1. Swords DS, Scaife CL (2021). Granular neighborhood-level socioeconomic data: An opportunity for a different kind of precision oncology? Am J Surg, 222(1), 8-9. ()
2. Scaife C (2019). SWSC 2019 Presidential address "Putting Patients First". Am J Surg, 218(6), 1035-1039. ()

Other

1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. United States. ()
2. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV (2021). Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (19(4), pp. 439-457). United States. ()
3. Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med (25(5), p. 861). United States. ()

Huntsman Cancer Institute News

• How a 25-Year-Old Utah Man Found Out He Had Colon Cancer
• Beating the Odds of Pancreas Cancer
• Translational Scholar: Courtney Scaife, MD

Podcasts

• Overwhelmed with Information on Colorectal Cancer Treatment? Talk to Your Doctor
• Do You Need a Whipple Procedure? All About the Surgery and Life Afterward